• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Surrogacy assessment using principal stratification when surrogate and outcome measures are multivariate normal.当替代指标和结局指标为多元正态分布时,使用主分层法进行代孕评估。
Biostatistics. 2014 Apr;15(2):266-83. doi: 10.1093/biostatistics/kxt051. Epub 2013 Nov 26.
2
Surrogacy assessment using principal stratification and a Gaussian copula model.使用主分层和高斯Copula模型进行代孕评估。
Stat Methods Med Res. 2017 Feb;26(1):88-107. doi: 10.1177/0962280214539655. Epub 2016 Jul 11.
3
Surrogacy assessment using principal stratification with multivariate normal and Gaussian copula models.使用主分层结合多元正态和高斯Copula模型的代孕评估。
Clin Trials. 2015 Aug;12(4):317-22. doi: 10.1177/1740774514561046. Epub 2014 Dec 9.
4
A bayesian approach to surrogacy assessment using principal stratification in clinical trials.在临床试验中使用主分层的贝叶斯代孕评估方法。
Biometrics. 2010 Jun;66(2):523-31. doi: 10.1111/j.1541-0420.2009.01303.x. Epub 2009 Aug 10.
5
Solutions for surrogacy validation with longitudinal outcomes for a gene therapy.基因治疗中具有纵向结局的代孕验证解决方案。
Biometrics. 2023 Sep;79(3):1840-1852. doi: 10.1111/biom.13720. Epub 2022 Jul 25.
6
Accommodating missingness when assessing surrogacy via principal stratification.通过主要分层评估代孕时,考虑缺失数据。
Clin Trials. 2013;10(3):363-77. doi: 10.1177/1740774513479522. Epub 2013 Apr 3.
7
Causal assessment of surrogacy in a meta-analysis of colorectal cancer trials.荟萃分析中对代孕因果关系的评估:结直肠癌试验。
Biostatistics. 2011 Jul;12(3):478-92. doi: 10.1093/biostatistics/kxq082. Epub 2011 Jan 20.
8
Incorporating baseline covariates to validate surrogate endpoints with a constant biomarker under control arm.在对照臂下,通过纳入基线协变量来验证具有恒定生物标志物的替代终点。
Stat Med. 2021 Dec 20;40(29):6605-6618. doi: 10.1002/sim.9201. Epub 2021 Sep 15.
9
A new proportion measure of the treatment effect captured by candidate surrogate endpoints.候选替代终点所捕获的治疗效果的一种新的比例度量。
Stat Med. 2014 Aug 30;33(19):3338-53. doi: 10.1002/sim.6180. Epub 2014 Apr 29.
10
Validation of surrogate endpoints in cancer clinical trials via principal stratification with an application to a prostate cancer trial.通过主分层法验证癌症临床试验中的替代终点及其在一项前列腺癌试验中的应用
Stat Med. 2017 Aug 30;36(19):2963-2977. doi: 10.1002/sim.7318. Epub 2017 May 8.

引用本文的文献

1
Validation of a Longitudinal Marker as a Surrogate Using Mediation Analysis and Joint Modeling: Evolution of the PSA as a Surrogate of the Disease-Free Survival.使用中介分析和联合模型验证纵向标志物作为替代指标:前列腺特异性抗原作为无病生存期替代指标的演变
Biom J. 2025 Aug;67(4):e70064. doi: 10.1002/bimj.70064.
2
Surrogate Marker Evaluation: A Tutorial Using R.替代标志物评估:使用R语言的教程
Stat Med. 2025 May;44(10-12):e70048. doi: 10.1002/sim.70048.
3
A General Framework to Assess Complex Heterogeneity in the Strength of a Surrogate Marker.评估替代标志物强度中复杂异质性的通用框架。
Stat Med. 2025 Feb 28;44(5):e70001. doi: 10.1002/sim.70001.
4
A Bayesian Approach to Modeling Variance of Intensive Longitudinal Biomarker Data as a Predictor of Health Outcomes.一种将密集纵向生物标志物数据的方差建模为健康结果预测指标的贝叶斯方法。
Stat Med. 2024 Dec 30;43(30):5748-5764. doi: 10.1002/sim.10281. Epub 2024 Nov 14.
5
A rank-based approach to evaluate a surrogate marker in a small sample setting.基于等级的方法在小样本设置中评估替代标志物。
Biometrics. 2024 Jan 29;80(1). doi: 10.1093/biomtc/ujad035.
6
Flexible evaluation of surrogate markers with Bayesian model averaging.贝叶斯模型平均法的替代标志物灵活评估。
Stat Med. 2024 Feb 20;43(4):774-792. doi: 10.1002/sim.9986. Epub 2023 Dec 11.
7
Can earlier biomarker measurements explain a treatment effect on diabetes incidence? A robust comparison of five surrogate markers.早期生物标志物测量能否解释对糖尿病发病率的治疗效果?五种替代标志物的稳健比较。
BMJ Open Diabetes Res Care. 2023 Oct;11(5). doi: 10.1136/bmjdrc-2023-003585.
8
Surrogacy validation for time-to-event outcomes with illness-death frailty models.利用疾病-死亡脆弱性模型对生存事件结局进行替代验证。
Biom J. 2024 Jan;66(1):e2200324. doi: 10.1002/bimj.202200324. Epub 2023 Sep 29.
9
Informed decision-making: Statistical methodology for surrogacy evaluation and its role in licensing and reimbursement assessments.知情决策:代理评估的统计方法及其在许可和报销评估中的作用。
Pharm Stat. 2022 Jul;21(4):740-756. doi: 10.1002/pst.2219.
10
Evaluation of Surrogate Endpoints Using Information-Theoretic Measure of Association Based on Havrda and Charvat Entropy.基于哈弗达和查瓦特熵的信息论关联度量法对替代终点的评估
Mathematics (Basel). 2022 Feb;10(3). doi: 10.3390/math10030465. Epub 2022 Jan 31.

本文引用的文献

1
Surrogate measures and consistent surrogates.替代指标与一致性替代指标
Biometrics. 2013 Sep;69(3):561-9. doi: 10.1111/biom.12071.
2
A Bayesian approach to improved estimation of causal effect predictiveness for a principal surrogate endpoint.一种用于改进主要替代终点因果效应预测性估计的贝叶斯方法。
Biometrics. 2012 Sep;68(3):922-32. doi: 10.1111/j.1541-0420.2011.01736.x. Epub 2012 Feb 20.
3
Evaluating correlation-based metric for surrogate marker qualification within a causal correlation framework.在因果关联框架内评估基于相关性的替代标志物合格性指标。
Biometrics. 2012 Jun;68(2):617-27. doi: 10.1111/j.1541-0420.2011.01682.x. Epub 2011 Nov 7.
4
Bayesian inference for partially identified models.部分可识别模型的贝叶斯推断。
Int J Biostat. 2010;6(2):Article 17. doi: 10.2202/1557-4679.1206.
5
Principal stratification--uses and limitations.主分层——用途与局限性
Int J Biostat. 2011;7(1). doi: 10.2202/1557-4679.1329. Epub 2011 Jul 11.
6
Sufficient conditions for concluding surrogacy based on observed data.基于观测数据得出代孕结论的充分条件。
Stat Med. 2011 Aug 30;30(19):2422-34. doi: 10.1002/sim.4273. Epub 2011 May 17.
7
A bayesian approach to surrogacy assessment using principal stratification in clinical trials.在临床试验中使用主分层的贝叶斯代孕评估方法。
Biometrics. 2010 Jun;66(2):523-31. doi: 10.1111/j.1541-0420.2009.01303.x. Epub 2009 Aug 10.
8
Response to Andrew Dunning's comment on 'evaluating a surrogate endpoint at three levels, with application to vaccine development'.对安德鲁·邓宁就“三个层面评估替代终点及其在疫苗研发中的应用”所做评论的回应。
Stat Med. 2009 Feb 15;28(4):716-9. doi: 10.1002/sim.3503.
9
ASSESSING SURROGATE ENDPOINTS IN VACCINE TRIALS WITH CASE-COHORT SAMPLING AND THE COX MODEL.采用病例队列抽样和Cox模型评估疫苗试验中的替代终点
Ann Appl Stat. 2008 Mar;2(1):386-407. doi: 10.1214/07-AOAS132.
10
Evaluating candidate principal surrogate endpoints.评估候选主要替代终点。
Biometrics. 2008 Dec;64(4):1146-54. doi: 10.1111/j.1541-0420.2008.01014.x. Epub 2008 Mar 24.

当替代指标和结局指标为多元正态分布时,使用主分层法进行代孕评估。

Surrogacy assessment using principal stratification when surrogate and outcome measures are multivariate normal.

作者信息

Conlon Anna S C, Taylor Jeremy M G, Elliott Michael R

机构信息

Department of Biostatistics, University of Michigan, Ann Arbor, MI 48109, USA.

出版信息

Biostatistics. 2014 Apr;15(2):266-83. doi: 10.1093/biostatistics/kxt051. Epub 2013 Nov 26.

DOI:10.1093/biostatistics/kxt051
PMID:24285772
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4023321/
Abstract

In clinical trials, a surrogate outcome variable (S) can be measured before the outcome of interest (T) and may provide early information regarding the treatment (Z) effect on T. Using the principal surrogacy framework introduced by Frangakis and Rubin (2002. Principal stratification in causal inference. Biometrics 58, 21-29), we consider an approach that has a causal interpretation and develop a Bayesian estimation strategy for surrogate validation when the joint distribution of potential surrogate and outcome measures is multivariate normal. From the joint conditional distribution of the potential outcomes of T, given the potential outcomes of S, we propose surrogacy validation measures from this model. As the model is not fully identifiable from the data, we propose some reasonable prior distributions and assumptions that can be placed on weakly identified parameters to aid in estimation. We explore the relationship between our surrogacy measures and the surrogacy measures proposed by Prentice (1989. Surrogate endpoints in clinical trials: definition and operational criteria. Statistics in Medicine 8, 431-440). The method is applied to data from a macular degeneration study and an ovarian cancer study.

摘要

在临床试验中,替代结局变量(S)可在感兴趣的结局(T)之前进行测量,并可能提供有关治疗(Z)对T的效应的早期信息。使用弗兰加基斯和鲁宾(2002年。因果推断中的主分层。生物统计学58,21 - 29)引入的主替代框架,我们考虑一种具有因果解释的方法,并在潜在替代指标和结局指标的联合分布为多元正态时,开发一种用于替代验证的贝叶斯估计策略。从给定S的潜在结局时T的潜在结局的联合条件分布,我们从该模型中提出替代验证指标。由于该模型无法从数据中完全识别,我们提出一些合理的先验分布和假设,这些可以应用于弱识别参数以辅助估计。我们探讨了我们的替代指标与普伦蒂斯(1989年。临床试验中的替代终点:定义和操作标准。医学统计学8,431 - 440)提出的替代指标之间的关系。该方法应用于黄斑变性研究和卵巢癌研究的数据。